Chromosomes 1, 3, 4, 15, and 16 show lateral asymmetry after replication in the presence of BrdU and staining with Giemsa at pH 10.4. Lateral asymmetry is thought to result from an unequal interstrand distribution of thymine in regions of repetitive DNA. Compound lateral asymmetry in 1 may be due to the presence of two segments of DNA differing in base composition and with different strands rich in thymine. Polymorphism for lateral asymmetry is observed in the AT-rich quinacrine-positive centromeric regions of 3 and 4, even though none of the four satellite DNAs are demonstrable by in situ hybridization there. Other workers have shown that a satellite fraction isolated using Hoechst 33258 and an Eco Rl restriction fragment of human satellite DNA map on 3. There is no evidence for the presence of satellite DNA on 4. Since 20% of the DNA in the human genome reassociates at a C₀t of ≤ 1 and only 4% is satellite DNA, 4 may have repetitive nonsatellite sequences; on the other hand the lack of an appropriate satellite probe may be the limiting factor. Lateral asymmetry in the Y has been demonstrated using the Hoechst method by other workers but cannot be observed with BrdU-Giemsa staining at pH 10.4.

This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.